 Home > Active Ingredient News > Drugs Articles > First oral drug for COVID-19 approved

First oral drug for COVID-19 approved

 Last Update: 2021-12-08
 Source: Internet
 Author: User

Tags

parkinson's disease death

reverse phase

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The British Medicines and Healthcare Products Administration (MHRA) has approved Merck’s molnupiravir for the treatment of adult patients with mild to moderate COVID-19 who have a positive SARS-CoV-2 diagnostic test and have at least one risk factor for serious disease
.

Merck said the US FDA is reviewing the emergency use authorization (EUA) application for molnupiravir

Molnupiravir (MK-4482, EIDD-2801) is a potent oral ribonucleoside analog that inhibits the replication of SARS-CoV-2.
This drug is the first oral antiviral drug approved for the treatment of COVID-19
.

The approval is based on the positive results of the interim analysis of the Phase 3 MOVe-OUT clinical trial
.

The MOVe-OUT trial (MK-4482-002) (NCT04575597) is a global phase 3, randomized, placebo-controlled, double-blind, multi-center study.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

FDA approves the first oral drug for COVID-19, which can reduce the risk of hospitalization or death by 88%

01-10

Related Products

Tirzepatide Lyophilized powder Vial 5mg 10mg 15mg 20mg 30mg customize 99% Purity with third side checking report

CAS No.: 2023788-19-2

Pharmacy Grade

$50-60/UNIT FOB

Wight loss Lyophilized Semaglutide Petide powder CAS 910463-68-2 with 99.9% purity

CAS No.: 910463-68-2

Pharmacy Grade

$140-175/G FOB

High Quality (E,E,E,E)-Squalene CAS NO 111-02-4 GMP ISO9001 EP Pharma grade Manufacture

CAS No.: 111-02-4

EP Pharma grade

$400-405/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

First oral drug for COVID-19 approved

Related Articles

FDA approves the first oral drug for COVID-19, which can reduce the risk of hospitalization or death by 88%